Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, Cervantes-Sánchez I, Espitia-Ríos ME, Estrada-Domínguez P, Jiménez-Alvarado R, Fermín-Caminero DJ, García-Camacho AS, Gómez Rosas P, Grimaldo-Gómez FA, Guzmán-Mera P, Herrera-Olivares W, Martínez-Ramírez MA, Medina-Meza C, Mena-Zepeda V, Montoya-Jiménez L, Morales-Adrián JJ, Morales-Hernández AE, Mujica-Martínez A, Palma-Moreno OG, Reyes-Brena G, Reynoso-Pérez AC, Salazar-Ramírez Ó, Hernández-Ruiz E, Paredes-Lozano EP, Alvarado-Ibarra M

Language: Spanish
References: 10
Page: 124-130
PDF size: 290.88 Kb.

ABSTRACT

Hodgkin’s lymphoma is a rare neoplasm in Mexico, even so, we do not have solid statistics that allow the precision of epidemiology, as well as diagnostic tools, classification and treatment according to international standards, it is limited in our medium, which forces us to make an effort in standardization to optimize resources and maximize the benefits in the care of our patients. This is the first general work in the form of consensus for the approach, classification, diagnosis and treatment in the patients of ISSSTE with Hodgkin’s lymphoma. Undoubtedly, in the coming years, this population can be improved, with better access to diagnostic and treatment tools that will modify the evolution and outcomes of patients in our group. This document contains a general review of the disease, which can be deepened in the near future, including new treatment modalities, but there is no doubt that it will be a strong pillar of the treatment and can replace those currently use.

REFERENCES

1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105(11):1684-1692. doi:10.1038/bjc.2011.450.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. doi:10.3322/caac.21387.

3. Hu E, Hufford S, Lukes R, et al. Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncol 1988;6(8):1285-1292. doi:10.1200/JCO.1988.6.8.1285.

4. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein- Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9(3):405-411. doi:10.1016/S1074-7613(00)80623-8.

5. Roemer MGM, Ligon AH, Engert A, et al. Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and treatment outcomes in patients with classical Hodgkin lymphoma treated with nivolumab (PD-1 Blockade). Blood 2016;128(22):2923-2923.

6. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015;372(17):1598-1607. doi:10.1056/ NEJMoa1408648.

7. Advani RH, Hoppe RT, Baer D, Mason J. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013 Apr;24(4):1044-8. doi: 10.1093/annonc/mds542.

8. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2016;28(27):4199-4206. doi:10.1200/JCO.2010.29.8018.

9. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. http:// dxdoiorg/101056/NEJMoa1002965. 2010;363(19):1812- 1821. doi:10.1056/NEJMoa1002965.

10. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab Vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2016;30(18):2183-2189. doi:10.1200/JCO.2011.38.0410.